Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung ...

The data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.

The regulatory approval in the EU comes approximately six months after Novocure secured FDA approval of the system.

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

Prolonged disease control can be maintained for patients with advanced non-small cell lung cancer (NSCLC) who discontinue ...

More information on all MD Anderson AACR Annual Meeting content can be found at MDAnderson.org/AACR. Targeted small molecule ...

Research Journal Features Genprex Collaborators' Abstract Detailing Positive Preclinical Data on the Use ofReqorsa® Gene Therapy for the Tre ...

Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in ...

Devoid of any marketed drugs, investors are set to focus on VSTM's pipeline updates when it reports first-quarter 2025 ...

Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.